1. Introduction {#sec1}
===============

Since pro-inflammatory mediators participate in knee osteoarthritis (OA) initiation, targeting inflammatory cascades is considered a promising way to prevent OA progression \[[@bib1]\]. Otherwise, it is also known that these inflammatory cytokines deteriorate the cellular antioxidant capacity to induce the senescence-associated secretory phenotype in chondrocytes and subsequently accelerate the degradation of cartilaginous extracellular matrix (ECM) in the knee joint \[[@bib2]\]. Accordingly, interventions to improve the anti-inflammatory and antioxidant capacities of cells are proposed to treat early stage OA \[[@bib3]\].

Several studies have reported that pre-treatment of chondrocytes with bioactive compounds can protect cells from pro-inflammatory cytokines. For example, the flavonoid baicalein has been proposed to treat OA for its anti-inflammatory, antioxidant, anti-tumor, anti-bacterial, anti-apoptotic, and anxiolytic effects, \[[@bib4]\]. Human chondrocytes pre-treated with baicalein inhibited the interleukin-1 beta (IL-1β)-induced expression of *a disintegrin and metalloproteinase with thrombospondin motifs* (*ADAMTS*)-*4*, *ADAMTS-5*, *cathepsins*, and *inducible nitric oxide synthase* (*iNOS*) mRNA; it also inhibited nitric oxide (NO) production \[[@bib5]\]. Similarly, baicalein down-regulated the expression of *matrix metalloproteinase* (*MMP*)-*1*, *MMP*-*3*, and *MMP*-*13* in IL-1β-stimulated human articular chondrocytes *in vitro* \[[@bib6]\]. Another study found that baicalein treatment prior to IL-1β/tumor necrosis factor-alpha (TNF-α) stimulation attenuated apoptosis and reduced MMP-3 and MMP-13 secretions in human chondrocytes by inhibiting NO production and the downstream caspase signaling pathway \[[@bib7]\]. It was shown that pre-treatment with baicalein could activate the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway to suppress the IL-6 expression in human osteoarthritic chondrocytes \[[@bib8]\]. Other protective effects of baicalein on oxidative stress-induced DNA damage and apoptosis have also been demonstrated \[[@bib9]\].

Even though these findings provide solid evidence of the therapeutic potential of baicalein to treat knee OA, the experimental condition such as pre-treatment of baicalein prior to inflammatory cytokine-stimulation may not actually represent the clinical reality. Patients who diagnosed with Kellgren--Lawrence grade II even III knee OA frequently suffer from pain and mobility impairment and have been exposure to inflammatory situation for a long time. Therefore, the therapeutic effects of post-treatment baicalein on osteoarthritic chondrocytes should be considered and examined.

2. Materials and methods {#sec2}
========================

2.1. Isolation and culture of human articular chondrocytes {#sec2.1}
----------------------------------------------------------

The retrieval and use of human tissues were reviewed and approved by the Institutional Review Board of the hospital (ECKIRB1080502). Written informed consent was provided by the eight Kellgren--Lawrence grade IV knee OA patients (five females and three males) with an average age of 72.4 years (range 58--79 years) enrolled in this study. Isolation of articular chondrocyte was performed as a previous study \[[@bib10]\]. In brief, the articular cartilage tissues were harvested from the intact lateral compartment of the knee during total knee replacement surgery, and the samples were sectioned as thin tissue slices and minced into fragments using a scalpel. The tissues were first treated with 0.1% protease (P8811, Sigma--Aldrich, St Louis, MO, USA) for 30 min, then digested with 0.2% type II collagenase (9001-12-1; Gibco, Life Technologies, Grand Island, NY, USA) overnight. Digested tissues were collected and washed twice with phosphate-buffered saline (PBS). The isolated cells were cultured in Dulbecco\'s modified Eagle\'s medium/Ham\'s Nutrient Mixture F-12 (DMEM/F-12, D8900, Sigma--Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (SH30396.03, Hyclone, Logan, UT, USA), and 1% antibiotic (15140-122, Gibco, Grand Island, NY, USA) in an incubator set at 37 °C and 5% CO~2~. The culture medium was changed every two to three days. The cells (P2--P5) obtained from each donor were cultured and studied independently.

2.2. Evaluation of toxicity of baicalein to chondrocytes {#sec2.2}
--------------------------------------------------------

Human chondrocytes were seeded into the 96-well culture plate (5000 cells/well) and cultured in regular DMEM/F-12 medium overnight. The cells were then washed twice with PBS and subsequent cultured in medium containing 0 (control), 5, 10, 25 and 50 μM baicalein (bai, 465119, Sigma--Aldrich, St Louis, MO, USA). After 24 h cultivation, the morphology of baicalein-treated chondrocytes was observed. The culture media were collected to measure the lactate dehydrogenase (LDH) release (G1780, CytoTox 96® NonRadioactive Cytotoxicity Assay, Promega, WI, USA). Finally, the cells were cultured in serum-free DMEM/F12 medium containing 10% water-soluble tetrazolium salt-1 reagent (11644807001, Roche, Mannheim, Germany) for 3 h to evaluate the mitochondrial activity.

2.3. IL-1β stimulation and baicalein application {#sec2.3}
------------------------------------------------

Based on the results of baicalein cytotoxicity, medium containing 25 μM baicalein was selected for further study. After being cultured in DMEM/F-12 medium overnight, the chondrocytes were stimulated with 10 ng/mL IL-1β (579402, BioLegend, San Diego, CA, USA) for 24 h. The stimulated cells were washed twice and cultured in baicalein-containing media for additional 24 h. The LDH release and mitochondrial viability were determined as in the previous section. In addition, cell survival was identified using a live/dead double staining assay (R37601, LIVE/DEAD® Cell Imaging Kit, Thermo Fisher Scientific, Waltham, MA, USA). Senescent cells were also detected based on the presence of β-galactosidase (β-gal, K320-250, senescence detection kit, Biovision, Milpitas, CA, USA).

2.4. Semi-quantitative real-time polymerase chain reaction (PCR) analysis {#sec2.4}
-------------------------------------------------------------------------

After being exposed to IL-1β for 24 h and cultured in baicalein-containing media for an additional 24 h, the total RNA of chondrocytes was extracted (R2052 Direct-zol™ RNA MiniPrep Kit, Zymo Research, Irving, CA, USA). RNA yield was quantified using a nanodrop spectrophotometer, and the RNA was reverse transcribed into cDNA by reverse-transcription polymerase chain reaction (PCR) (T100™ Thermal cycler, Bio-Rad, Hercules, CA, USA) using a cDNA synthesis kit (RR037A, PrimeScript™ RT Reagent Kit, TaKaRa Bio Inc., Shiga, Japan). The semi-quantitative gene expression levels of cells were analyzed by using the real-time PCR (QuantStudio 3 Real-Time PCR system, Thermo Fisher Scientific, Waltham MA, USA) with the Taqman system (4444556, Applied Biosystems™ TaqMan™ Fast Advanced Master Mix, Applied Biosystems, Waltham, MA, USA) or the SYBR Green system (A25741, Applied Biosystems™ PowerUp™ SYBR™ Green Master Mix, Applied Biosystems, Waltham, MA, USA). Pro-inflammatory cytokine expression, including expression of *iNOS*, *IL-1β*, *IL-6*, *IL-8*, *IL-10*, and *TNF-α*, was determined. The ECM-related genes, including *MMP-3*, *MMP-9*, *MMP-13*, *tissue inhibitor of metalloproteinase* (*TIMP*)-*1*, *aggrecan* (*AGCN*), *collagen type I (COL1A1)*, and *collagen type II* (*COL2*) were also evaluated. In addition, the cell proliferation marker *Ki-67* and the phenotype marker *Sirt1* were analyzed. The mRNA expression of each target gene was normalized to that of the house keeping gene glyceraldehyde 3-phosphate dehydrogenase.

2.5. Quantification of anabolic and catabolic cytokines by enzyme-linked immunosorbent assay (ELISA) {#sec2.5}
----------------------------------------------------------------------------------------------------

The culture supernatants of treated chondrocytes were collected to quantify the pro-inflammatory cytokines. The levels of IL-1β (88--7010; eBioscience, San Diego, CA, USA), IL-6 (88--7066; eBioscience, San Diego, CA, USA), IL-8 (BMS204/3TEN, affymetrix; eBioscience, San Diego, CA, USA), IL-10 (88--7106; eBioscience, San Diego, CA, USA), TNF-α (88--7340; eBioscience, San Diego, CA, USA), MMP-3 (DY513; R&D Systems, Minneapolis, MN, USA), MMP-9 (DY911; R&D Systems, Minneapolis, MN, USA), TIMP-1 (DY970; R&D Systems, Minneapolis, MN, USA), and TIMP-2 (DY971; R&D Systems, Minneapolis, MN, USA) in supernatants were determined using a relevant enzyme-linked immunosorbent assay (ELISA) along with a spectrophotometer.

2.6. Western blotting {#sec2.6}
---------------------

The chondrocytes were lysed by radioimmunoprecipitation assay buffer with protease inhibitor cocktail (Roche, Indianapolis, IN, USA) for protein extraction, and protein concentration was determined using the bicinchoninic acid (BCA) assay (23227, Pierce™ BCA protein assay kit, Thermo Fisher Scientific, Waltham MA, USA). Twenty μg of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), and incubated with anti-phospho-Nrf2 (ab180844, Abcam, Cambridge, UK), anti-Nrf2 (ab62352, Abcam, Cambridge, UK), anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB, 10745-1-AP, Proteintech, Rosemont, IL, USA), anti-p50 (14220-1-AP, Proteintech, Rosemont, IL, USA), anti-cyclooxygenase-2 (COX-2, 66351-1-lg, Proteintech, Rosemont, IL, USA), and anti-β-actin (MA5-15739, Thermo Fisher Scientific, Waltham MA, USA) antibodies at 4 °C overnight. Protein expression was detected with a chemiluminescence reagent (SuperSignal West Pico PLUS Chemiluminescent Substrate, Thermo Fisher Scientific, Waltham MA, USA) and imaged using a Western blot imaging/gel documentation system (Invitrogen iBright FL1000 Imaging System, Thermo Fisher Scientific, Waltham MA, USA). The band of each targeting protein was quantified and expressed as relative densitometry.

2.7. Statistical analysis {#sec2.7}
-------------------------

Data obtained from each group were expressed as mean ± standard error. One way ANOVA was used to analyze the differences among groups. A difference was considered statistically significant when the value of p was \< 0.05. For the asterisks on figures, \* represents p \< 0.05, \*\* represents p \< 0.01, and \*\*\* represents p \< 0.001.

3. Results {#sec3}
==========

3.1. High dose baicalein is cytotoxic to human articular chondrocytes {#sec3.1}
---------------------------------------------------------------------

After being cultured in baicalein-containing media for 24 h, the viability and LDH release of chondrocytes were determined. Application of 50 μM baicalein to cells significantly increased LDH release (p \< 0.05, [Fig. 1](#fig1){ref-type="fig"}A) and decreased mitochondrial activity (p \< 0.05, [Fig. 1](#fig1){ref-type="fig"}B) when compared with those of the control group. Although no significant differences were noticed in LDH release nor mitochondrial activity among the 5, 10, and 25 μM baicalein groups, the mitochondrial activity of the above three groups was significantly lower than that of the control group (p \< 0.05). Unlike the cobble-stone morphology seen in the control group, the application of baicalein to chondrocytes resulted in a slightly extended pseudopod appearance ([Fig. 1](#fig1){ref-type="fig"}C). Otherwise, no hypertrophic transformation was noticed in baicalein-treated cells.Fig. 1Dose-dependent toxicity of baicalein to chondrocytes. (A) Application of 50 μM baicalein on human chondrocytes significantly increased LDH release. (B) Chondrocytes treated 50 μM baicalein also had a decrease in mitochondrial activity. (C) Chondrocytes in control group had a cobble-stone morphology, and application of baicalein on cells resulted in a slightly extending pseudopodia in appearance.Fig. 1

3.2. IL-1β stimulation and baicalein application {#sec3.2}
------------------------------------------------

Exposure to IL-1β for 24 h significantly increased the LDH level (p \< 0.01, [Fig. 2](#fig2){ref-type="fig"}A) and impaired mitochondrial activity (p \< 0.01, [Fig. 2](#fig2){ref-type="fig"}B) relative to those of the control group. Application of 25 μM baicalein to IL-1β-stimulated chondrocytes decreased LDH release (p \< 0.05) and restored mitochondrial activity (p \< 0.05) when compared with those of the IL-1β group. However, IL-1β-stimulated chondrocytes treated with 25 μM baicalein still had a significantly higher LDH level (p \< 0.05) and lower mitochondrial activity (p \< 0.05) than those of the control group.Fig. 2The effects of baicalein to IL-1β-stimulated chondrocytes. (A) Application of 25 μM baicalein decreased LDH release to stimulated cells. (B) The mitochondrial activity of chondrocytes was partially restored. (C) IL-1β exposure transformed chondrocytes to an irregular morphology, resulted in an increase in the number of dead cells, and caused cell senescence. Baicalein application decreased the number of dead cells, but the hypertrophic morphology and the cell senescence were not changed.Fig. 2

IL-1β stimulation transformed chondrocytes into an irregular morphology and resulted in an increase in the number of dead cells (red fluorescence) as well as senescent cells (β-gal staining, blue color). Although baicalein application decreased the number of dead cells, the hypertrophic morphology and cell senescence were not ameliorated ([Fig. 2](#fig2){ref-type="fig"}C).

3.3. Baicalein did not correct mRNA expression of pro-inflammatory cytokines {#sec3.3}
----------------------------------------------------------------------------

IL-1β exposure significantly up-regulated the mRNA expression of *iNOS* (p \< 0.01), *IL-1β* (p \< 0.001), *TNF-α* (p \< 0.05), *IL-6* (p \< 0.001), *IL-8* (p \< 0.001), *MMP-3* (p \< 0.001), *MMP-9* (p \< 0.01), *MMP-13* (p \< 0.01), *COL1A1* (p \< 0.05) and *Ki-67* (p \< 0.001); and down-regulated the expression of *AGCN* (p \< 0.01) and *COL2A1* (p \< 0.05) in treated chondrocytes, relative to those of the control group ([Fig. 3](#fig3){ref-type="fig"}). However, IL-1β stimulation caused no substantial changes in *IL-10*, *TIMP-1* and *Sirt1* expression in chondrocytes. Baicalein application significantly down-regulated the mRNA expression of *IL-1β* (p \< 0.01), *TNF-α* (p \< 0.05), *MMP-3* (p \< 0.05), *MMP-9* (p \< 0.01), and *Ki-67* (p \< 0.01), and up-regulated *IL-10* (p \< 0.05), *AGCN* (p \< 0.05), and *COL2A1* (p \< 0.05) when compared with IL-1β-stimulated cells. However, baicalein did not change the expression of levels of *iNOS*, *IL-6*, *IL-8*, *MMP-13*, *COL1A1*, *TIMP-1* and *Sirt1* in treated chondrocytes.Fig. 3The mRNA expressions of baicalein-treated chondrocytes. IL-1β exposure significantly up-regulated the mRNA expressions of *iNOS*, *IL-1β*, *TNF-α*, *IL-6*, *IL-8*, *MMP-3*, *MMP-9*, *MMP-13, Ki-67, COL1A1* and down-regulated *AGCN*, *COL2A1* to chondrocytes relative to those of control group. Baicalein application significantly down-regulated the mRNA expression of *IL-1β*, *TNF-α*, *MMP-3*, *MMP-9*, *Ki-67* and up-regulated *IL-10*, *AGCN*, *COL2A1* when compared with those of IL-1β-stimulated cells. However, baicalein did not change *iNOS*, *IL-6*, *IL-8*, *TIMP-1*, *COL1A1* and *Sirt1* levels in treated chondrocytes.Fig. 3Fig. 4Influence of baicalein on anabolic and catabolic cytokines. The cellular productions of IL-1β, TNF-α, IL-6, IL-8, IL-10, MMP-3, MMP-9 were increased while the TIMP-1 was decreased upon IL-1β stimulation. However, the TIMP-2 was not influenced in stimulated-chondrocytes. Baicalein application decreased TNF-α, MMP-3, MMP-9, TIMP-2 protein levels and further increased IL-10 in IL-1β-stimulated chondrocytes. However, the synthases of IL-1β, IL-6, IL-8 and TIMP-1 were not changed.Fig. 4

3.4. Influence of baicalein on anabolic and catabolic cytokines {#sec3.4}
---------------------------------------------------------------

In chondrocytes, external IL-1β stimulation increased cellular production of IL-1β (p \< 0.01), TNF-α (p \< 0.001), IL-6 (p \< 0.001), IL-8 (p \< 0.001), IL-10 (p \< 0.01), MMP-3 (p \< 0.001), and MMP-9 (p \< 0.01); it decreased TIMP-1 (p \< 0.01), but TIMP-2 production was not changed. Baicalein application to IL-1β-stimulated chondrocytes decreased TNF-α (p \< 0.01), MMP-3 (p \< 0.01), MMP-9 (p \< 0.05), and TIMP-2 (p \< 0.05) protein levels and increased IL-10 level (p \< 0.01). However, the synthesis of IL-1β, IL-6, IL-8, and TIMP-1 were not changed.

3.5. Baicalein modulates NF-κB and p50 syntheses {#sec3.5}
------------------------------------------------

Relative to the control group, the p-Nrf2/Nrf2 ratio increased dramatically in IL-1β-exposed chondrocytes, and the syntheses of NF-κB, p50, and COX-2 were also increased ([Fig. 5](#fig5){ref-type="fig"}). Baicalein application did not change the p-Nrf2/Nrf2 ratio obviously. Otherwise, in IL-1β-stimulated cells, baicalein further increased COX-2 synthesis while NF-κB and p50 synthesis were decreased.Fig. 5Western blot of baicalein-treated chondrocytes. (A) p-Nrf2/Nrf2 ratio increased dramatically in IL-1β-exposed chondrocytes, and the syntheses of NF-κB, p50, and COX-2 were also increased relative to those of control group. (B) In spite of the p-Nrf2/Nrf2 ratio was not changed obviously in IL-1β stimulated cells, baicalein application decreased NF-κB and p50 productions. However, baicalein further increased COX-2 synthesis.Fig. 5

4. Discussion {#sec4}
=============

Both proinflammatory cytokines and oxidative stress participate in OA initiation and development, and thus, targeting inflammatory and antioxidant cascades have been proposed as an useful way to prevent the progression of knee OA. Although the therapeutic effects of pre-treatment of osteoarthritic chondrocytes with baicalein have been shown, the effects of baicalein post-treatment has not been fully elucidated.

The possible cytotoxicity of baicalein in human chondrocytes was studied first. Previous studies reported that 50--100 μM baicalein had no adverse effect on cell viability nor did it cause cell death in human chondrocytes \[[@bib5], [@bib6], [@bib7]\]. However, Li et al. found that high dose baicalein (100 μM) did not impair viability to primary rat chondrocytes \[[@bib11]\]. Our experiments reveal that human knee OA chondrocytes display more sensitive potential to the cytotoxicity of baicalein than health chondrocytes. Likewise, another study showed that 50 μM baicalein had no cytotoxic effects on rat nucleus pulposus cells \[[@bib12]\]. However, Zandi et al. noticed that baicalein (50, 100, and 200 μM) dramatically impaired the viability of kidney epithelial Vero cells \[[@bib13]\]. Li et al. also found that baicalein (50 and 100 μM) decreased the viability HeLa cells \[[@bib14]\]. Similarly, 150 μM baicalein showed deleterious effects on HEI-193 human schwannoma cells \[[@bib15]\]. These studies indicate that the cytotoxic dose of baicalein may depend on the cell type. In addition, our results showed that 50 μM baicalein slightly increased LDH release and decreased mitochondrial viability ([Fig. 1](#fig1){ref-type="fig"}). It is known that the severity of OA influences the responses of chondrocytes to external stimulation \[[@bib16]\]. Taken these researches and the result in this study, human OA chondrocytes may have different potential sensitivity to the toxicity of baicalein.

Human chondrocyte exposure to IL-1β resulted in hypertrophic transformation, cell death, impaired cell viability, and cell senescence \[[@bib17]\]. We also noticed that IL-1β stimulation resulted in up-regulations in *COL1A1*, *MMP-13*, and down-regulations in *COL2A1* ([Fig. 3](#fig3){ref-type="fig"}), which were evidences for hypertrophic differentiation of chondrocytes \[[@bib18],[@bib19]\]. We also noticed that baicalein treatment after inflammation stimulation alleviated cell death and partially recovered mitochondrial viability, while the senescence-associated secretory phenotype was not affected in chondrocytes ([Fig. 2](#fig2){ref-type="fig"}). In fact, baicalein has been proposed as an antioxidant and shown to stimulate free radical formation \[[@bib20]\]. Since excessive oxidative stress is known to cause cell senescence and apoptosis in chondrocytes, the dose-dependent toxicity of baicalein in chondrocytes should be further studied. Furthermore, chondrocyte hypertrophic transformation is known to play a role in early and late stage OA \[[@bib21]\].

IL-1β stimulation caused a serious inflammatory reaction in human chondrocytes ([Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}). Otherwise, the cartilage-specific ECM synthesis was also disturbed through down-regulations in *AGCN*, *COL2A1* and up-regulation in *COL1A1* and *MMPs* mRNA expressions. Even though baicalein post-treatment decreased the mRNA expressions and protein productions of *IL-1β*, *TNF-α*, *MMP-3*, and *MMP-9*, the levels were consistently higher than those of the control group. Several studies found that pre-treat with baicalein in chondrocytes down-regulated the IL-1β-induced *MMP-1, MMP-3, MMP-9* and *MMP*-13 mRNA expressions dramatically in a dose-dependent manner \[[@bib5], [@bib6], [@bib7]\], and baicalein application also decreased the of MMP-3, MMP-9, and COX-2 protein productions \[[@bib11]\]. Otherwise, we found that baicalein post-treatment decreased *MMP-3* and *MMP-9* levels slightly. Furthermore, the mRNA expression of *MMP-13* was not changed in IL-1β-stimulated chondrocytes. In addition, other studies reported that baicalein pre-treatment (25 and 50 μM) down-regulated *iNOS* mRNA expression in IL-1β-treated human chondrocytes and nucleus pulposus cells efficiently \[[@bib5],[@bib12]\]. However, this study showed that baicalein post-treatment did not decrease the *iNOS* expression in chondrocytes. In addition to MMPs, Jin et al. reported that baicalein pre-treatment (25 and 50 μM) also down-regulated *IL-*6 mRNA expression in IL-1β-stimulated nucleus pulposus cells \[[@bib12]\]. However, our findings showed that baicalein post-treatment did not affect either *IL-6* expression or IL-6 production. A high level of IL-6 in synovial fluid was found to be associated with the increasement of MMP-1 and MMP-3 levels in OA patients \[[@bib22]\]. We also noticed that *IL-8*, another highly secreted inflammatory cytokine in the synovial fluid of OA patients, was up-regulated in IL-1β-stimulated chondrocytes, even after treatment with baicalein. IL-8 is also known to induce chondrocyte hypertrophic differentiation \[[@bib23]\]. Furthermore, IL-6 and IL-8 are known to synergistically stimulate cartilage ECM degradation, and thus the concern of highly expressed IL-6 and IL-8 cannot be ignored \[[@bib24]\].

Another interesting finding of baicalein post-treatment was the up-regulation of *IL-*10 mRNA expression as well as IL-10 protein synthesis in IL-1β-stimulated chondrocytes. The role of IL-10 in OA pathophysiology is not fully understood, but IL-10 has been proven to inhibit osteoarthritic chondrocyte proliferation and *MMP-3* expression \[[@bib25],[@bib26]\]. Therefore, we hypothesize that baicalein post-treatment up-regulated *IL-10* may further down-regulate *MMP-3* as well as the proliferative marker *Ki-67*. Furthermore, up-regulation of *TIMP-1* and restored *AGCN* and *COL2A1* expressions in baicalein post-treatment chondrocyte were also found. Previously, Zhang et al. also showed that baicalein attenuated collagen type II and glycosaminoglycans loss in stimulated mouse articular cartilage explants \[[@bib7]\]. IL-10 overexpression is known to antagonize *AGCN* expression, which is down-regulated by TNF-α stimulation \[[@bib27]\]. Based on these findings, our study reveals that baicalein post-treatment may restore cartilage-specific ECM synthesis through the up-regulation in *IL-10* and down-regulation of *TNF-α*. Moreover, other research also showed baicalein application partially restored *SOX-9*, a phenotype marker of chondrocyte in IL-1β-stimulated rat articular chondrocytes \[[@bib11]\]. On the contrary, *Sirt1*, a gene involved in the chondrocyte hypertrophy, was still found to be disrupted in our study \[[@bib28]\].

Similar to the study by Jeong et al., we showed that IL-1β stimulation enhanced phosphorylation of Nrf2 \[[@bib15]\]. Whereas they showed that baicalein pre-treatment further increased p-Nrf2/Nrf2, baicalein post-treatment did not change the ratio in our study. In contrast to the report of Khan et al. that baicalein pre-treatment activated the Nrf2 signaling pathway to suppress IL-6 expression in human osteoarthritic chondrocytes, we showed that baicalein post-treatment did not further enhance Nrf2 signaling to suppress IL-6 \[[@bib8]\]. By analysis of p65 synthesis, Li et al. showed that baicalein inhibited NF-κB pathway, which is in consist with our finding in the suppression of p50 and NF-κB \[[@bib11]\].

A limitation of this study is the therapeutic effects of baicalein application on IL-1β-stimulated human knee OA chondrocytes were studied at one time-point only (4--24 h). In spite of our previous study found that the effective period of antioxidant was relatively short \[[@bib10]\], Li et al. study showed that the functions of baicalein on IL-1β-stimulated rat articular chondrocytes was time-dependent \[[@bib11]\]. Therefore, the long-term effects of baicalein on knee OA shall be further demonstrated.

5. Conclusion {#sec5}
=============

We studied the benefits of baicalein post-treatment to osteoarthritic chondrocytes. Baicalein post-treatment alleviated cell death and partially recovered mitochondrial viability, while the senescence-associated secretory phenotype was not improved in IL-1β-stimulated human chondrocytes. Baicalein down-regulated *IL-1β*, *TNF-α*, *MMP-3*, *MMP-9* and *MMP-13* expressions to stimulated cells; however, levels of these factors were still higher than those of normal chondrocytes. Moreover, *iNOS*, *IL-6, IL-8* and *COLA1A1* were consistently highly expressed, and *IL-10* protein production was further increased in stimulated cells even after baicalein was provided. Baicalein post-treatment suppressed NF-κB and p50 production while the downstream COX-2 was still highly expressed. The benefits of baicalein post-treatment to osteoarthritic chondrocytes was showed in this study which implying a possible treatment to OA patients especially in the homeostasis of cartilaginous ECM. Therefore, more studies in baicalein is needed.
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